This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Introduction/Depression and Its Subtypes: A Treatment Update

Jerrold F. Rosenbaum, M.D.

Published: January 1, 1998

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Despite the considerable advance in recent years in our understanding of thecourse and treatment of major depressive disorder, psychiatry remains challenged by significant gaps in our understanding of the etiology of the disorder andin the adequacy of our therapeutics. Although the minority of patients seekingtreatment for major depression will be refractory, the majority, despite our treatmentefforts, will endure residual symptoms, continued impairment, and recurrences.For a disorder with the adverse social and health impact of major depressionand a lifetime prevalence of about 15% of the population, the motivation to do betteris compelling.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 59

Quick Links: Depression (MDD)

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...